rc 3095 has been researched along with gemcitabine in 1 studies
| Studies (rc 3095) | Trials (rc 3095) | Recent Studies (post-2010) (rc 3095) | Studies (gemcitabine) | Trials (gemcitabine) | Recent Studies (post-2010) (gemcitabine) |
|---|---|---|---|---|---|
| 108 | 2 | 26 | 12,523 | 3,208 | 6,923 |
| Protein | Taxonomy | rc 3095 (IC50) | gemcitabine (IC50) |
|---|---|---|---|
| Chain A, DEOXYNUCLEOSIDE KINASE | Drosophila melanogaster (fruit fly) | 0.76 | |
| Equilibrative nucleoside transporter 1 | Homo sapiens (human) | 0.19 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hong, SK; Yang, KX; Yang, SY; Yin, SH | 1 |
1 other study(ies) available for rc 3095 and gemcitabine
| Article | Year |
|---|---|
RC-3095, a gastrin-releasing peptide receptor antagonist, synergizes with gemcitabine to inhibit the growth of human pancreatic cancer CFPAC-1 in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Bombesin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Immunohistochemistry; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Peptide Fragments; Receptors, Bombesin; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |